These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37885919)

  • 1. Cross-sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease.
    Ally M; Sugarman MA; Zetterberg H; Blennow K; Ashton NJ; Karikari TK; Aparicio HJ; Frank B; Tripodis Y; Martin B; Palmisano JN; Steinberg EG; Simkin I; Farrer LA; Jun GR; Turk KW; Budson AE; O'Connor MK; Au R; Goldstein LE; Kowall NW; Killiany R; Stern RA; Stein TD; McKee AC; Qiu WQ; Mez J; Alosco ML
    Alzheimers Dement (Amst); 2023; 15(4):e12492. PubMed ID: 37885919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression.
    Rabl M; Zullo L; Lewczuk P; Kornhuber J; Karikari TK; Blennow K; Zetterberg H; Bavato F; Quednow BB; Seifritz E; von Gunten A; Clark C; Popp J
    Alzheimers Res Ther; 2024 Jul; 16(1):165. PubMed ID: 39054505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment.
    Kivisäkk P; Carlyle BC; Sweeney T; Trombetta BA; LaCasse K; El-Mufti L; Tuncali I; Chibnik LB; Das S; Scherzer CR; Johnson KA; Dickerson BC; Gomez-Isla T; Blacker D; Oakley DH; Frosch MP; Hyman BT; Aghvanyan A; Bathala P; Campbell C; Sigal G; Stengelin M; Arnold SE
    Front Neurol; 2023; 14():1069411. PubMed ID: 36937522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
    Benedet AL; Milà-Alomà M; Vrillon A; Ashton NJ; Pascoal TA; Lussier F; Karikari TK; Hourregue C; Cognat E; Dumurgier J; Stevenson J; Rahmouni N; Pallen V; Poltronetti NM; Salvadó G; Shekari M; Operto G; Gispert JD; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Zimmer ER; Zetterberg H; Molinuevo JL; Paquet C; Rosa-Neto P; Blennow K; Suárez-Calvet M;
    JAMA Neurol; 2021 Dec; 78(12):1471-1483. PubMed ID: 34661615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia.
    Ingannato A; Bagnoli S; Mazzeo S; Giacomucci G; Bessi V; Ferrari C; Sorbi S; Nacmias B
    Front Endocrinol (Lausanne); 2024; 15():1375302. PubMed ID: 38654932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression.
    Rabl M; Zullo L; Lewczuk P; Kornhuber J; Karikari TK; Blennow K; Zetterberg H; Bavato F; Quednow BB; Seifritz E; von Gunten A; Clark C; Popp J
    Res Sq; 2024 Mar; ():. PubMed ID: 38562890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of plasma amyloid beta
    Verberk IMW; Thijssen E; Koelewijn J; Mauroo K; Vanbrabant J; de Wilde A; Zwan MD; Verfaillie SCJ; Ossenkoppele R; Barkhof F; van Berckel BNM; Scheltens P; van der Flier WM; Stoops E; Vanderstichele HM; Teunissen CE
    Alzheimers Res Ther; 2020 Sep; 12(1):118. PubMed ID: 32988409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of plasma neurofilament light chain and glial fibrillary acidic protein in subjective cognitive decline and mild cognitive impairment.
    Mazzeo S; Ingannato A; Giacomucci G; Bagnoli S; Cavaliere A; Moschini V; Balestrini J; Morinelli C; Galdo G; Emiliani F; Piazzesi D; Crucitti C; Frigerio D; Polito C; Berti V; Padiglioni S; Sorbi S; Nacmias B; Bessi V
    Neurol Sci; 2024 Mar; 45(3):1031-1039. PubMed ID: 37723371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer's disease.
    Yang Z; Sreenivasan K; Toledano Strom EN; Osse AML; Pasia LG; Cosme CG; Mugosa MRN; Chevalier EL; Ritter A; Miller JB; Cordes D; Cummings JL; Kinney JW
    Alzheimers Res Ther; 2023 Nov; 15(1):190. PubMed ID: 37924152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer's disease-associated biomarkers alterations among de novo Parkinson's disease patients: a prospective cohort study.
    Liu T; Zuo H; Ma D; Song D; Zhao Y; Cheng O
    J Neuroinflammation; 2023 Jul; 20(1):167. PubMed ID: 37475029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma p-tau
    Frank B; Ally M; Brekke B; Zetterberg H; Blennow K; Sugarman MA; Ashton NJ; Karikari TK; Tripodis Y; Martin B; Palmisano JN; Steinberg EG; Simkina I; Turk KW; Budson AE; O'Connor MK; Au R; Goldstein LE; Jun GR; Kowall NW; Stein TD; McKee AC; Killiany R; Qiu WQ; Stern RA; Mez J; Alosco ML
    Alzheimers Dement; 2022 Aug; 18(8):1523-1536. PubMed ID: 34854549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer's disease.
    Parvizi T; König T; Wurm R; Silvaieh S; Altmann P; Klotz S; Rommer PS; Furtner J; Regelsberger G; Lehrner J; Traub-Weidinger T; Gelpi E; Stögmann E
    Front Aging Neurosci; 2022; 14():887498. PubMed ID: 36072480
    [No Abstract]   [Full Text] [Related]  

  • 14. Relationship between topological efficiency of white matter structural connectome and plasma biomarkers across the Alzheimer's disease continuum.
    Zhang M; Chen H; Huang W; Guo T; Ma G; Han Y; Shu N
    Hum Brain Mapp; 2024 Jan; 45(1):e26566. PubMed ID: 38224535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy.
    Chouliaras L; Thomas A; Malpetti M; Donaghy P; Kane J; Mak E; Savulich G; Prats-Sedano MA; Heslegrave AJ; Zetterberg H; Su L; Rowe JB; O'Brien JT
    J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):651-658. PubMed ID: 35078917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive blood biomarkers and brain changes associated with age-related cognitive decline.
    Saunders TS; Pozzolo FE; Heslegrave A; King D; McGeachan RI; Spires-Jones MP; Harris SE; Ritchie C; Muniz-Terrera G; Deary IJ; Cox SR; Zetterberg H; Spires-Jones TL
    Brain Commun; 2023; 5(3):fcad113. PubMed ID: 37180996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower White Matter Volume and Worse Executive Functioning Reflected in Higher Levels of Plasma GFAP among Older Adults with and Without Cognitive Impairment.
    Asken BM; VandeVrede L; Rojas JC; Fonseca C; Staffaroni AM; Elahi FM; Lindbergh CA; Apple AC; You M; Weiner-Light S; Brathaban N; Fernandes N; Boxer AL; Miller BL; Rosen HJ; Kramer JH; Casaletto KB
    J Int Neuropsychol Soc; 2022 Jul; 28(6):588-599. PubMed ID: 34158138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer's disease.
    Sugarman MA; Zetterberg H; Blennow K; Tripodis Y; McKee AC; Stein TD; Martin B; Palmisano JN; Steinberg EG; Simkin I; Budson AE; Killiany R; O'Connor MK; Au R; Qiu WWQ; Goldstein LE; Kowall NW; Mez J; Stern RA; Alosco ML
    Neurobiol Aging; 2020 Oct; 94():60-70. PubMed ID: 32585491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia.
    Frontera JA; Boutajangout A; Masurkar AV; Betensky RA; Ge Y; Vedvyas A; Debure L; Moreira A; Lewis A; Huang J; Thawani S; Balcer L; Galetta S; Wisniewski T
    Alzheimers Dement; 2022 May; 18(5):899-910. PubMed ID: 35023610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia.
    Thijssen EH; Verberk IMW; Kindermans J; Abramian A; Vanbrabant J; Ball AJ; Pijnenburg Y; Lemstra AW; van der Flier WM; Stoops E; Hirtz C; Teunissen CE
    Alzheimers Dement (Amst); 2022; 14(1):e12285. PubMed ID: 35603139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.